355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449
Rudin C, Von Hoff D, LoRusso P, Vernillet L, Yauch R, Darbonne W, Mackey H, de Sauvage F, Low J, Reddy J. 355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449. European Journal Of Cancer Supplements 2008, 6: 112-113. DOI: 10.1016/s1359-6349(08)72289-4.Peer-Reviewed Original ResearchA first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors
LoRusso P, Rudin C, Borad M, Vernillet L, Darbonne W, Mackey H, DiMartino J, de Sauvage F, Low J, Von Hoff D. A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors. Journal Of Clinical Oncology 2008, 26: 3516-3516. DOI: 10.1200/jco.2008.26.15_suppl.3516.Peer-Reviewed Original Research